A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer

Abstract

Currently, pathological evaluation of stage I/II colon cancer, following the Union Internationale Contre Le Cancer (UICC) guidelines, is insufficient to identify patients that would benefit from adjuvant treatment. In our study, we analyzed tissue samples from 276 patients with colon cancer utilizing mass spectrometry imaging. Two distinct approaches are herein presented for data processing and analysis. In one approach, four different machine learning algorithms were applied to predict the tendency to develop metastasis, which yielded accuracies over 90% for three of the models. In the other approach, 1007 m/z features were evaluated with regards to their prognostic capabilities, yielding two m/z features as promising prognostic markers. One feature was identified as a fragment from collagen (collagen 3A1), hinting that a higher collagen content within the tumor is associated with poorer outcomes. Identification of proteins that reflect changes in the tumor and its microenvironment could give a very much-needed prediction of a patient's prognosis, and subsequently assist in the choice of a more adequate treatment.

Keywords: MALDI; colon cancer; mass spectrometry imaging; proteomics; tumor prognosis.

Figure 1

(A) KM curve for the occurrence of distant metastasis. Patients are stratified based on PAM classification of m/z 1821.83. (B) KM curve for patient survival. Patients are stratified based on PAM classification of m/z 1821.83. (C) KM curve for the occurrence of distant metastasis. Patients are stratified based on PAM classification of m/z 1303.06. (D) KM curve for overall survival. Patients are stratified based on PAM classification of m/z 1303.06.